First patient dosed in Ph 1 trial of IMC-P115C in patients with PRAME-expressing tumors December 25, 2024
Initial clinical results from ongoing KYANITE-1 study of inhaled KB707 in patients with solid tumors of the lung announced December 25, 2024
Safety Review Committee Approval of Opening 3rd Cohort and Preliminary Results from 1st Cohort in Ph 1 TTX-MC138 Trial Announced December 25, 2024
Elevation Oncology Expands Pipeline with Nomination of EO-1022 for the Treatment of HER3-expressing Solid Tumors December 18, 2024
Rondo Therapeutics Closes $67 Million Series A Financing to Advance Next-Generation Immuno-Oncology Platform for Solid Tumors December 10, 2024
Relay Therapeutics & Elevar Therapeutics Announce Exclusive Global Licensing Agreement for Lirafugratinib in FGFR2-Driven Cholangiocarcinoma and Other Solid Tumors December 10, 2024
Gilead and Tubulis Enter Into Exclusive Option and License Agreement to Develop ADC Candidate for Select Solid Tumor Target December 10, 2024
First Patient Enrolled in Ph 1a/b Study of PRMT5 Inhibitor GTA182 for MTAP-Deleted Solid Tumors November 26, 2024
First Patient dosed in Ph 1/2 Clinical Study of GPR65 Inhibitor PTT-4256 in Patients with Advanced Solid Cancers November 26, 2024
Positive CHMP Opinion for Repotrectinib for the Treatment of Advanced ROS1-Positive NSCLC and Advanced NTRK-Positive Solid Tumors November 19, 2024
FDA Fast Track Designation for ALE.P02 for the Treatment of CLDN1+ Squamous Solid Tumors November 19, 2024
IDEAYA Nominates IDE034, a B7H3/PTK7 Topo-I-Payload Bispecific ADC and Option Exercise with Biocytogen November 19, 2024
ARTBIO to Enter into Licensing and Research Partnership with 3B Pharmaceuticals to Advance a First-in-Class Alpha Radioligand Therapy for Solid Tumors November 19, 2024
Promising Preliminary Results of Investigator-Initiated Ph 1 Trial of Keytruda and LYMPHIR™ in Cancer Patients with Recurrent Solid Tumors Announced November 19, 2024
